Molecular mimicry and multiple sclerosis

Neural Regeneration Research

Volumn 6, Issue 17, 2011, Pages 1322-1333

  Namaka, Michael ^a,b   Kapoor, Sabina ^a   Simms, Leann ^a   Leong, Christine ^a   Grossberndt, Amy ^a   Prouta, Michael ^a   Frost, Emma ^a   Esfahani, Farid ^b   Gomori, Andrew ^b   Mulvey, Michael R ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antibodies; Autoimmune diseases; Molecular mimicry; Multiple sclerosis; Neurodegenerative diseases

Indexed keywords

BACTERIAL ANTIGEN; EPITOPE; HEPATITIS B VACCINE; HLA ANTIGEN; MYELIN PROTEIN; VIRUS ANTIGEN;

ANTIGENICITY; CD4+ T LYMPHOCYTE; CHLAMYDOPHILA PNEUMONIAE; CROSS REACTION; DEMYELINATION; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HAEMOPHILUS INFLUENZAE; HLA SYSTEM; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOPATHOGENESIS; INFECTION RISK; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VIRUS IMMUNITY;

EID: 79960849854     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2011.17.008     Document Type: Review

References (168)

1. Sadovnick AD, Baird PA, and Ward RH. Multiple sclerosis: updated risks for relatives. Am J Med Genet. 1988;29:533-541.
2. Olerup O, and Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens. 1991;38:1-15.
3. Willer CJ, Dyment DA, Risch NJ, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci. 2003;100:12877-12882.
4. Poser CM. The role of trauma in the pathogenesis of multiple sclerosis: a review. Clin Neurol Neurosurg. 1994;96:103-110.
5. Tortorella C, Bellacosa A, Paolicelli D, et al. 2005. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. J Neurol Sci. 2005;239:95-99.
6. Confavreux C. and Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606-616.
7. Confavreux C. and Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129:595-605.
8. Wynn DR, Rodriguez M, O'Fallon WM, et al. Update on the epidemiology of multiple sclerosis. Mayo Clin Proc. 1989;64: 808-817.
9. Sadovnick AD, and Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993;20:17-29.
10. Compston A. The epidemiology of multiple sclerosis: principles, achievements, and recommendations. Ann Neurol. 1994;36 Suppl 2:S211-217.
11. Ebers GC. Genetics and multiple sclerosis: an overview. Ann Neurol. 1994;36 Suppl: S12-14.
12. Hayes CE. Vitamin D: a natural inhibitor of multiple sclerosis. Proc Nutr Soc. 2000;59:531-535.
13. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev.1993;6:382-427.
14. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol. 2006;92:60-64.
15. Sibley WA, Bamford CR, and Clark K. Clinical viral infections and multiple sclerosis. Lancet. 1985;1:1313-1315.
16. Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science. 1986;234:596-601.
17. He J, McCarthy M, Zhou Y, et al. Infection of primary human fetal astrocytes by human herpesvirus 6. J Virol. 1996;70:1296-1300.
18. Dewhurst S. Human herpesvirus type 6 and human herpesvirus type 7 infections of the central nervous system. Herpes. 2004;11 Suppl 2:105A-111A.
19. Oberacher-Velten IM, Jonas JB, Junemann A, et al. Bilateral optic neuropathy and unilateral tonic pupil associated with acute human herpesvirus 6 infection: a case report. Graefes Arch Clin Exp Ophthalmol. 2005;243:175-177.
20. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci. 1995;92:7440-7444.
21. Goldberg SH, Albright AV, Lisak RP, et al. Polymerase chain reaction analysis of human herpesvirus-6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol. 1999;5:134-139.
22. Kim JS, Lee KS, Park JH, et al. Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients. Eur Neurol. 2000;43:170-173.
23. Opsahl ML, and Kennedy PG. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain. 2005;128:516-527.
24. Cermelli C, Berti R, Soldan SS, et al. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis. 2003;187:1377-1387.
25. Goodman AD, Mock DJ, Powers JM, et al. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J Infect Dis. 2003;187:1365-1376.
26. Tejada-Simon MV, Zang YC, Hong J, et al. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003;53:189-197.
27. Tejada-Simon MV, Zang YC, Hong J, et al. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J Virol. 2002;76:6147-6154.
28. Tait AE and Staus SK. Phosphorylation of U24 from Human Herpes Virus type 6 (HHV-6) and its potential role in mimicking myelin basic protein (MBP) in multiple sclerosis. FEBS Letters. 2008;82:2685-2688.
29. Martin C, Enbom M, Soderstrom M, et al. Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. Acta Neurol Scand. 1997;95:280-283.
30. Nielsen L, Larsen AM, Munk M, et al. Human herpesvirus-6 immunoglobulin G antibodies in patients with multiple sclerosis. Acta Neurol Scand. Suppl. 1997;169:76-78.
31. Enbom M, Wang FZ, Fredrikson S, et al. Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls. Clin Diagn Lab Immunol. 1999;6:545-549.
32. Enbom M, Linde A, and Evengard B. No evidence of active infection with human herpesvirus 6 (HHV-6) or HHV-8 in chronic fatigue syndrome. J Clin Microbiol. 2000;38:2457.
33. Taus C, Pucci E, Cartechini E, et al. Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2000;101:224-228.
34. Xu Y, Linde A, Fredrikson S, et al. HHV-6 A-or B-specific P41 antigens do not reveal virus variant-specific IgG or IgM responses in human serum. J Med Virol. 2002;66:394-399.
35. Ahram M, El-Omar A, Bahoe Y, et al. Association between human herpesvirus 6 and occurrence of multiple sclerosis among Jordanian patients. Acta Neurol Scand. 2009;120:430-435.
36. Alvarez-Lafuente R, Martinez A, Garcia-Montojo M, et al. MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients. Eur J of Neurol. 2010;17:129-135.
37. de-The G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 1978;274: 756-761.
38. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med. 1989;320:689-695.
39. Evans AS, Rothfield NF, and Niederman JC. Raised antibody titres to E.B. virus in systemic lupus erythematosus. Lancet. 1971;1:167-168.
40. Tsokos GC, Magrath IT, and Balow JE. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol. 1983;131:1797-1801.
41. Tosato G, Steinberg AD, Yarchoan R, et al. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest. 1984;73: 1789-1795.
42. Vergnon JM, Vincent M, de The G, et al. Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association? Lancet. 1984;2: 768-771.
43. Whittingham S, McNeilage J, and Mackay IR. Primary Sjogren's syndrome after infectious mononucleosis. Ann Intern Med. 1985; 102:490-493.
44. Yamaoka K, Miyasaka N, and Yamamoto K. Possible involvement of Epstein-Barr virus in polyclonal B cell activation in Sjogren's syndrome. Arthritis Rheum. 1988;31:1014-1021.
45. Nagasaki M, Morikawa S, Harada T, et al. A novel EBV-related nucleo-cytoplasmic antigen in a null cell-line (HLN-STL-C) reactive to antibodies in the sera from patients with Sjogren's syndrome. J Autoimmun. 1989;2:457-462.
46. Vento S, Guella L, Mirandola F, et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet. 1995;346:608-609.
47. Vrbikova J, Janatkova I, Zamrazil V, et al. Epstein-Barr virus serology in patients with autoimmune thyroiditis. Exp Clin Endocrinol Diabetes. 1996;104:89-92.
48. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;100:3019-3026.
49. Sumaya CV, Myers LW, and Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol. 1980;37:94-96.
50. Hernan MA, Zhang SM, Lipworth L, et al. Multiple sclerosis and age at infection with common viruses. Epidemiology. 2001;12: 301-306.
51. Sumaya CV, Myers LW, Ellison GW, et al. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol. 1985;17:371-377.
52. Bray PF, Bloomer LC, Salmon VC, et al. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol. 1983;40:406-408.
53. Larsen PD, Bloomer LC, and Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology. 1985;35:435-438.
54. Shirodaria PV, Haire M, Fleming E, et al. Viral antibody titers. Comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch Neurol. 1987;44:1237-1241.
55. Wagner HJ, Munger KL, and Ascherio A. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis. Eur J Neurol. 2004;11:833-834.
56. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA. 2005; 293:2496-2500.
57. Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology. 2000;55:178-184.
58. Ferrante P, Omodeo-Zorini E, Zuffolato MR, et al. Human T-cell lymphotropic virus tax and Epstein-Barr virus DNA in peripheral blood of multiple sclerosis patients during acute attack. Acta Neurol Scand. Suppl. 1997;169:79-85.
59. Sundstrom P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology. 2004;62:2277-2282.
60. Craig JC, Haire M, Millar JH, et al. Immunological control of Epstein-Barr virus-transformed lymphocytes in multiple sclerosis. Clin Immunol Immunopathol. 1983;29:86-93.
61. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005;115: 1352-1360.
62. Hay KA, Tenser RB. Leukotropic herpesviruses in multiple sclerosis. Mult Scler. 2000;6:66-68.
63. Virtanen JO, Zabriskie JB, Siren V, et al. Co-localization of human herpes virus 6 and tissue plasminogen activator in multiple sclerosis brain tissue. Med Sc. Monit. 2005;11:BR84-87.
64. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology. 2000;11:220-224.
65. Wucherpfennig KW, Hafler DA. A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann NY Acad Sci. 1995;756:241-258.
66. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002;3:940-943.
67. Holmoy T, Kvale EO, Vartdal F. Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J Neurovirol. 2004;10:278-283.
68. Wucherpfennig KW, Sette A, Southwood S, et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med. 1994;179:279-290.
69. Ota K, Matsui M, Milford EL, et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990;346:183-187.
70. Datta AK, Feighny RJ, and Pagano JS. Induction of Epstein-Barr virus-associated DNA polymerase by 12-O-tetradecanoylphorbol-13-acetate. Purification and characterization. J Biol Chem. 1980; 255:5120-5125.
71. Furnari FB, Adams MD, and Pagano JS. Regulation of the Epstein-Barr virus DNA polymerase gene. J Virol. 1992;66: 2837-2845.
72. Cook PJ, and Honeybourne D. Clinical aspects of Chlamydia pneumoniae infection. Presse Med. 1995;24:278-282.
73. Ngeow Y. The many faces of chlamydiae. Malays J Pathol. 2000; 22:55-64.
74. Sriram S, Mitchell W, and Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology. 1998;50:571-572.
75. Sriram S, Stratton CW, Yao S, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol. 1999;46:6-14.
76. Layh-Schmitt G, Bendl C, Hildt U, et al. Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis. Ann Neurol. 2000;47:652-655.
77. Derfuss T, Gurkov R, Then Bergh F, et al. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain. 2001;124: 1325-1335.
78. Yao SY, Ljunggren-Rose A, Stratton CW, et al. Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of Chlamydia pneumoniae antigens. J Interferon Cytokine Res. 2001;21: 137-146.
79. Chapman MD, Hartley JC, Furrows SJ, et al. Lack of serum oligoclonal antibody responses to Chlamydophila pneumoniae in multiple sclerosis. Eur Neurol. 2005;53:81-83.
80. Hammerschlag MR, Apfalter P, Boman J, et al. The role of Chlamydia pneumoniae in multiple sclerosis: real or fictitious? J Infect Dis. 2005;192:1305-1307.
81. Boman J, Roblin PM, Sundstrom P, et al. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology. 2000;54:265.
82. Kaufman M, Gaydos CA, Sriram S, et al. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult Scler. 2002;8:289-294.
83. Sriram S. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology. 2000;55: 1423-1424.
84. Tang YW, Sriram S, Li H, et al. Qualitative and Quantitative Detection of Chlamydophila pneumoniae DNA in Cerebrospinal Fluid from Multiple Sclerosis Patients and Controls. PLOS One. 2009;4:e5200.
85. Lenz DC, Lu L, Conant SB, et al. A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats. J Immunol. 2001;167:1803-1808.
86. Conant SB, and Swanborg RH. MHC class II peptide flanking residues of exogenous antigens influence recognition by autoreactive T cells. Autoimmun Rev. 2003;2:8-12.
87. Murphy TF, and Kasper DT. Infections due to Haemophilus influenzae, other Haemophilus species, the HACEK group, and other gram-negative bacilli. In: Braunwald E. and Fauci A. S. eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 1998;924-928.
88. Ulanova M, Tsang RS. Invasive Haemophilus influenzae disease: changing epidemiology and host-parasite interactions in the 21st century. Infect Genet Evol. 2009;9:594-605.
89. Waite S, Jeudy J, and White CS. Acute lung infections in normal and immunocompromised hosts. Radiol Clin North Am. 2006;44: 295-315.
90. Fluckiger U, and Trampuz A. Pneumonia in the immune compromised host. Ther Umsch. 2001;58:614-619.
91. Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barre syndrome. Brain. 2000;123: 2171-2178.
92. Koga M, Koike S, Hirata K, et al. Ambiguous value of Haemophilus influenzae isolation in Guillain-Barre and Fisher syndromes. J Neurol Neurosurg Psychiatry. 2005;76: 1736-1738.
93. Vartdal F, Vandvik B, and Norrby E. Viral and bacterial antibody responses in multiple sclerosis. Ann Neurol. 1980;8:248-255.
94. DeStefano F, Gu D, Kramarz P, et al. Childhood vaccinations and risk of asthma. Pediatr Infect Dis. J. 2002;21:498-504.
95. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. MMWR Surveill. Summ. 2003;52:1-24.
96. Bath S, Bisgard K, and Murphy T. Epidemiology and Surveillance Div, National Immunization Program; K Shutt, MPH, N Rosenstein, MD, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; C Ohuabunwo, MBBS, EIS Officer, CDC JAMA. 2002;287:2206-2207.
97. Scheifele D, Halperin S, Law B, et al. Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. CMAJ. 2005;172:53-56.
98. Sheff B. Haemophilus influenzae Type B (Hib). Nursing. 2006; 36:31.
99. Olson JK, Croxford JL, Calenoff MA, et al. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest. 2001; 108:311-318.
100. Croxford JL, Anger HA, and Miller SD. Viral delivery of an epitope from Haemophilus influenzae induces central nervous system autoimmune disease by molecular mimicry. J Immunol. 2005;174: 907-917.
101. Croxford JL, Olson JK, Anger HA, et al. Initiation and exacerbation of autoimmune demyelination of the central nervous system via virus-induced molecular mimicry: implications for the pathogenesis of multiple sclerosis. J Virol. 2005;79:8581-8590.
102. Hughes LE, Smith PA, Bonell S, et al. Cross-reactivity between related sequences found in Acinetobacter sp., Pseudomonas aeruginosa, myelin basic protein and myelin oligodendrocyte glycoprotein in multiple sclerosis. J Neuroimmunol. 2003;144: 105-115.
103. Constantinescu CS, Wysocka M, Hilliard B, et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol. 1998;161:5097-5104.
104. Misko IS, Cross SM, Khanna R, et al. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Proc Natl Acad Sci USA. 1999;96:2279-2284.
105. Tang YW, and Stratton CW. Staphylococcus aureus: An old pathogen with new weapons. Clin Lab Med. 2010;30:179-208.
106. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998; 339:520-532.
107. Hu L, Umeda A, Kondo S, et al. Typing of staphylococcus aureus colonising human nasal carriers by pulsed-field gel electrophoresis. J Med Microbiol. 1995;42:127-132.
108. Paul MO, Lamikanra A, and Aderibigbe DA. Nasal carriers of coagulase-positive staphylococci in a nigerian hospital community. Trans R Soc Trop Med Hyg. 1982;76:319-323.
109. Leedom JM, Kennedy RP, Lepper MH, et al. Observations of the staphylococcal nasal carrier state. Ann NY Acad Sci. 1965;128: 381-403.
110. Torres BA, Kominsky S, Perrin GQ, et al. Superantigens: The good, the bad, and the ugly. Exp Biol Med. (Maywood) 2001;226: 164-176.
111. Brocke S, Gaur A, Piercy C, et al. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature. 1993;365:642-644.
112. Schiffenbauer J, Johnson HM, Butfiloski EJ, et al. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci USA. 1993;90: 8543-8546.
113. Hu L, Umeda A, Kondo S, et al. Typing of Staphylococcus aureus colonising human nasal carriers by pulsed-field gel electrophoresis. J Med Microbiol. 1995;42:127-132.
114. Graham PL 3rd, Lin SX, and Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med. 2006;144:318-325.
115. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis. 2006;193:172-179.
116. Mulvey MR, Doupe M, Prout M, et al. Staphylococcus aureus harbouring enterotoxin A as a possible risk factor for multiple sclerosis exacerbations. Multiple Sclerosis. 2011;17(4):397-403.
117. Emini EA, Ellis RW, Miller WJ, et al. Production and immunological analysis of recombinant hepatitis B vaccine. J Infect. 13 Suppl A: 1986;3-9.
118. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine. 1990;8 Suppl: S69-73;discussion. S79-80.
119. Hogenesch H, Azcona-Olivera J, Scott-Moncrieff C, Snyder PW, and Glickman Let al. Vaccine-induced autoimmunity in the dog. Adv Vet Med. 1999;41:733-747.
120. Fujinami RS, and Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science. 1985;230:1043-1045.
121. Bogdanos DP, Smith H, Ma Y, et al. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol. 2005;12:217-224.
122. Geier DA, and Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38:295-301.
123. Hernan MA, Jick SS, Olek MJ, et al. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004;63:838-842.
124. Sadovnick AD, and Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet. 2000;355:549-550.
125. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344: 327-332.
126. Touze E, Fourrier A, Rue-Fenouche C, et al. Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology. 2002;21:180-186.
127. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60:504-509.
128. Marks JS, and Halpin TJ. Guillain-Barre syndrome in recipients of A/New Jersey influenza vaccine. JAMA.1980;243:2490-2494.
129. Ropper AH, and Victor M. Influenza vaccination and the Guillain-Barre syndrome. N Engl J Med. 1998;339:1845-1846.
130. Myers LW, Ellison GW, Lucia M, et al. Swine-influenza vaccination in multiple sclerosis. N Engl J Med. 1976;295:1204.
131. Alter M, Kahana E, and Loewenson R. Migration and risk of multiple sclerosis. Neurology. 1978;28:1089-1093.
132. Gilden DH, Devlin ME, Burgoon MP, et al. The search for virus in multiple sclerosis brain. Mult Scler. 1996;2:179-183.
133. Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125:952-960.
134. Cirone M, Cuomo L, Zompetta C, et al. Human herpesvirus 6 and multiple sclerosis: a study of T cell cross-reactivity to viral and myelin basic protein antigens. J Med Virol. 2002;68:268-272.
135. van Noort JM, Bajramovic JJ, Plomp AC, et al. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol. 2000;105: 46-57.
136. Wucherpfennig KW, Sette A, Southwood S, et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med. 1994;179:279-290.
137. Wucherpfennig KW, and Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 1995;80:695-705.
138. Khan RB, Bertorini TE, and Levin MC. HTLV-1 and its neurological complications. Neurologist. 2001;7:271-278.
139. Levin MC, and Jacobson S. Cellular and humoral immune responses associated with HTLV-I associated myelopathy/tropical spastic paraparesis. Ann NY Acad Sci. 1997;835:142-152.
140. Levin MC, Krichavsky M, Berk J, et al. Neuronal molecular mimicry in immune-mediated neurologic disease. Ann Neurol. 1998;44:87-98.
141. Levin MC, Lee SM, Kalume F, et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med. 2002;8:509-513.
142. Levin MC, Lee SM, Morcos Y, et al. Cross-reactivity between immunodominant human T lymphotropic virus type I tax and neurons: implications for molecular mimicry. J Infect Dis. 2002; 186:1514-1517.
143. Srinivasappa J, Saegusa J, Prabhakar BS, et al. Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol. 1986;57:397-401.
144. Jardetzky TS, Brown JH, Gorga JC, et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 1994;368:711-718.
145. Sospedra M. and Martin R. Molecular mimicry in multiple sclerosis. Autoimmunity. 2006;39:3-8.
146. Hickey WF, Hsu BL, and Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res. 1991;28:254-260.
147. Bachmaier K, Neu N, de la Maza LM, et al. Chlamydia infections and heart disease linked through antigenic mimicry. Science. 1999;283:1335-1339.
148. Benagiano M, D'Elios MM, Amedei A, et al. Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J Immunol. 2005;174:6509-6517.
149. Ausiello CM, Fedele G, Palazzo R, et al. 60-kDa heat shock protein of Chlamydia pneumoniae promotes a T helper type 1 immune response through IL-12/IL-23 production in monocyte-derived dendritic cells. Microbes Infect. 2006;8: 714-720.
150. Abdulkarim AS, Petrovic LM, Kim WR, et al. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol. 2004;40:380-384.
151. Ramos M, Alvarez I, Sesma L, et al. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem. 2002;277:37573-37581.
152. Moran AP, Prendergast MM, and Appelmelk BJ. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol. 1996;16: 105-115.
153. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 2002;109: 797-804.
154. Klee L. and Zand R. Probable epitopes: Relationships between myelin basic protein antigenic determinants and viral and bacterial proteins. Neuroinformatics. 2004;2:59-70.
155. Prescott L, Harley J, and Klein D. Human diseases caused by bacteria. Microbiology. 2002;914.
156. Croxford JL, Olson JK, and Miller SD. Epitope spreading and molecular mimicry as triggers of autoimmunity in the Theiler's virus-induced demyelinating disease model of multiple sclerosis. Autoimmun Rev. 2002;1:251-260.
157. Bachmaier K, and Penninger JM. Chlamydia and antigenic mimicry. Curr Top Microbiol Immunol. 2005;296:153-163.
158. Sriram S, and Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol. 2005;58: 939-945.
159. Kristo A, Uhari M, Kontiokari T, et al. Nasal middle meatal specimen bacteriology as a predictor of the course of acute respiratory infection in children. Pediatr Infect Dis J. 2006;25: 108-112.
160. Wierzbowski AK, Hoban DJ, Hisanaga T, et al. The use of macrolides in treatment of upper respiratory tract infections. Curr Allergy Asthma Rep. 2006;6:171-181.
161. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110:105-123.
162. Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84:227-229.
163. Vlacha V, Forman EN, Miron D, et al. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics. 1996;97:738-739.
164. Faure E. Multiple sclerosis and hepatitis B vaccination: could minute contamination of the vaccine by partial hepatitis B virus polymerase play a role through molecular mimicry? Med Hypotheses. 2005;65:509-520.
165. Stratton CW, Weldon DB. Antimicrobial treatment of multiple sclerosis. Infection. 2005;34:342-344.
166. Sriram S, Yao SY, Stratton C, et al. Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS. J Neurol Sci. 2005;234:87-91.
167. Beers MH, Porter RS, Jones TV, et al. Allergic and Other Hypersensitivity Disorders. The Merck manual of diagnosis and therapy. 18th ed. Whitehouse Station (NJ): Merck Research Laboratories.
168. Friedman JE, Zabriskie JB, Plank C, et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler. 2005;11: 286-295.